We examined the usefulness of prostate specific antigen alph-1-antichymotrypsin complex (PSA-ACT) and its indices for the detection of prostate cancer in patients with a prostate specific antigen (PSA) level between 2.1 and 10.0 ng/ml. Between July 1999 and October 2001, 151 patients with a PSA level between 2.1 and 10.0 ng/ml underwent a systematic biopsy under transrectal ultrasound (TRUS) gu...

negative impact on quality of life [2-5]. Serum Prostate Specific Antigen (PSA) is a globally used screening tool for carcinoma prostate, based on which prostate biopsy largely recommended when PSA value exceeds 4 ng/ mL [6]. PSA blood level variation had been studied with respect to numerous factors including age, race, prostate volume (PV), androgen level, body mass index (BMI), creatinine, l...

Abstract Background The early detection of bone metastases is very important in prostate cancer follow-up. This study aimed to compare conventional tumor markers, namely free prostate-specific antigen (free PSA), total (total PSA/total PSA ratio, alkaline phosphatase (ALP) values, Gleason scores and 99 m Tc-MDP scintigraphy findings the prediction cancer. Methods In total, 175 patients with who...

background and objective: prostate cancer is a prevalent disease around the world. the prostatic specific antigen (psa) test has recently proved itself as a useful method for the diagnosis and examination of patients with prostatic cancer. the objective of this study was to compare the stability of free psa and total psa in different storage settings. materials and methods: samples were obtaine...

BACKGROUND We aimed to value the usefulness of free to total prostate-specific antigen and Prostate-specific antigen (PSA) density for prostate cancer in the patients with PSA levels of 4.0 ng/ml or less. METHODS A total of 343 subjects with PSA levels of 4.0 ng/ml or less were biopsied. All patients were divided into four groups according to the PSA levels: 0 to 1.0 ng/ml, 1.1 to 2.0 ng/ml, ...

Prostate-specific antigen (PSA) is a widely used marker for the diagnosis and management of prostate cancer. Minimal enhancer/promoter constructs derived from the 5' flank of the human PSA gene (prostate-specific enhancer) were inserted into adenovirus type 5 DNA so as to drive the E1A gene, thereby creating a prostate-specific enhancer-containing virus, CN706. E1A was expressed at high levels ...

Prostate specific antigen (PSA) is the common biomarker for prostate cancer (PCa). However, its lack of specificity to differentiate PCa from benign disorders stimulates search alternative biomarkers improve clinical management patients. Different studies have described changes in core-fucosylation level PSA between patients and healthy controls. To exploit these findings, we adapted an impedim...

introduction: prostate specific antigen (psa) is one of the most sensitive markers for diagnosis of prostate cancer. immunoradiometric kit (irma) is a common and sensitive method for determination of psa in clinical laboratories. this kit has four major components: solid phase coated with monocolonal antibody, pair antibody labelled with i-125, series of standards in different ranges of concent...

BACKGROUND Age-specific prostate specific antigen (PSA) cutoffs for prostate biopsy have been widely used in the USA and European countries. However, the application of age-specific PSA remains poorly understood in China. METHODS Between 2003 and 2012, 1,848 men over the age of 40, underwent prostate biopsy for prostate cancer (PCa) at Huashan Hospital, Shanghai, China. Clinical information a...